Buy Stocks Easy | About Us
September 28, 2021
Buy Stocks Easy | Online Stocks

PSTI


Buy Pluristem Therapeutics, Inc. Stock (symbol: PSTI) Easy Online

Company Name: Pluristem Therapeutics, Inc.

Symbol: PSTI

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

IPO: 2003

PSTI Current Share Price

Today's PSTI ( Pluristem Therapeutics, Inc. ) opening price: $

Yesterday's PSTI ( Pluristem Therapeutics, Inc. ) closing price: $

Pluristem Therapeutics, Inc. Stock ( symbol: PSTI ) Price Chart since IPO (2003):

12 Months Pluristem Therapeutics, Inc. Stock ( symbol: PSTI ) Price Chart

Popular Questions about Pluristem Therapeutics, Inc. Public Stock ( PSTI )

A: Pluristem Therapeutics, Inc. stock symbol (also called stock or share ticker) is PSTI

A: Pluristem Therapeutics, Inc. IPO (Initial Public Offering) took place on 2003

A: Pluristem Therapeutics, Inc.'s stock (PSTI symbol) price at ther IPO (initial Public Offering) was $

Q: Is PSTI stock worth buying at the moment?

A: If you were looking for a long-term investment portfolio and had bought the 'Pluristem Therapeutics, Inc. stock (symbol: PSTI) at the beginning of 2019, at the opening share price of $1.1500, with a minimum of $200, by now your shares would be worth $34982 and your profit would be $34782 - SHOW ONLY IF PROFIT.

Buy Pluristem Therapeutics, Inc. Stock Easy Online

Pluristem Therapeutics, Inc. Stock Ticker Price Chart since IPO:





Pluristem Therapeutics, Inc. Stock Price Yesterday



 


Pluristem Therapeutics, Inc. Stock Price – Last Week




 


Pluristem Therapeutics, Inc. Stock Price – Last Month




 


Pluristem Therapeutics, Inc. Stock Value Chart – 12 Months




            

                

                    

                    
                

                
                
Rate this post

                
            

            
            

             

            

        

    



            



    

        

            

                
 Latest Stock News: 

            

        

        



                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/17/1961466/0/en/Pluristem-Completes-75-Enrollment-in-its-Pivotal-Phase-III-CLI-Clinical-Study.html
                            

                                
Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

                                
                                
Patients unsuitable for revascularization surgery currently have no...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/665135/pluristem-therapeutics-shares-march-higher-can-it-continue
                            

                                
Pluristem Therapeutics Shares March Higher, Can It Continue?

                                
                                
As of late, it has definitely been a great time to be an investor P...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/03/1955421/0/en/Pluristem-Reaches-Milestone-in-its-Phase-III-Muscle-Injury-Study-Completes-50-Enrollment.html
                            

                                
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

                                
                                
Multinational study in the U.S., Israel and Europe targeting to be ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/12/1945226/0/en/Pluristem-Therapeutics-CEO-Issues-Shareholder-Update.html
                            

                                
Pluristem Therapeutics CEO Issues Shareholder Update

                                
                                
HAIFA, Israel, Nov.  12, 2019  (GLOBE NEWSWIRE) --  Pluristem Thera...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/588656/pluristem-therapeutics-sees-hammer-chart-pattern-time-to-buy
                            

                                
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

                                
                                
Pluristem Therapeutics has been struggling lately, but the selling ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/16/1916196/0/en/Pluristem-Therapeutics-Recaps-Key-Opinion-Leader-Call-Reviewing-Hematological-Programs.html
                            

                                
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

                                
                                
HAIFA, Israel, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Pluristem Thera...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/09/1912629/0/en/Pluristem-Therapeutics-to-Host-Key-Opinion-Leader-Call-on-Its-Acute-Radiation-Syndrome-and-Hematological-Programs.html
                            

                                
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

                                
                                
Data readout from second cohort of hematological study will be pres...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/21/1904740/0/en/Pluristem-Therapeutics-to-Host-Key-Opinion-Leader-Call-on-its-Acute-Radiation-Syndrome-and-Hematological-Deficiencies-Programs.html
                            

                                
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs

                                
                                
HAIFA, Israel, Aug.  21, 2019  (GLOBE NEWSWIRE) --  Pluristem Thera...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/17/1961466/0/en/Pluristem-Completes-75-Enrollment-in-its-Pivotal-Phase-III-CLI-Clinical-Study.html
                            

                                
Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

                                
                                
Patients unsuitable for revascularization surgery currently have no...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/665135/pluristem-therapeutics-shares-march-higher-can-it-continue
                            

                                
Pluristem Therapeutics Shares March Higher, Can It Continue?

                                
                                
As of late, it has definitely been a great time to be an investor P...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/12/03/1955421/0/en/Pluristem-Reaches-Milestone-in-its-Phase-III-Muscle-Injury-Study-Completes-50-Enrollment.html
                            

                                
Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

                                
                                
Multinational study in the U.S., Israel and Europe targeting to be ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/11/12/1945226/0/en/Pluristem-Therapeutics-CEO-Issues-Shareholder-Update.html
                            

                                
Pluristem Therapeutics CEO Issues Shareholder Update

                                
                                
HAIFA, Israel, Nov.  12, 2019  (GLOBE NEWSWIRE) --  Pluristem Thera...


                            

                        
                    

                


                            

                    


                        
                            http://www.zacks.com/stock/news/588656/pluristem-therapeutics-sees-hammer-chart-pattern-time-to-buy
                            

                                
Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

                                
                                
Pluristem Therapeutics has been struggling lately, but the selling ...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/16/1916196/0/en/Pluristem-Therapeutics-Recaps-Key-Opinion-Leader-Call-Reviewing-Hematological-Programs.html
                            

                                
Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

                                
                                
HAIFA, Israel, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Pluristem Thera...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/09/09/1912629/0/en/Pluristem-Therapeutics-to-Host-Key-Opinion-Leader-Call-on-Its-Acute-Radiation-Syndrome-and-Hematological-Programs.html
                            

                                
Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

                                
                                
Data readout from second cohort of hematological study will be pres...


                            

                        
                    

                


                            

                    


                        
                            http://www.globenewswire.com/news-release/2019/08/21/1904740/0/en/Pluristem-Therapeutics-to-Host-Key-Opinion-Leader-Call-on-its-Acute-Radiation-Syndrome-and-Hematological-Deficiencies-Programs.html
                            

                                
Pluristem Therapeutics to Host Key Opinion Leader Call on its Acute Radiation Syndrome and Hematological Deficiencies Programs

                                
                                
HAIFA, Israel, Aug.  21, 2019  (GLOBE NEWSWIRE) --  Pluristem Thera...


                            

                        
                    

                


            
        

    




    
    





	
	  

	  All right reserved Buy Stocks Easy , 2019.